Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. Dr. Tardif graduated from the University of Montreal with his medical degree in 1987 and completed his training in cardiology and research in Montreal and Boston in 1994. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal Pfizer-endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC).
His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as early clinical trials and large international randomized clinical trials. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases including COLCOT and REDUCE-IT. Dr. Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine, the latter originally funded by the Network of Centers of Excellence of Canada.
Dr. Tardif has authored more than 700 scientific articles and has won multiple awards during his career, including the Research Achievement Award of the Canadian Cardiovascular Society, the Distinguished Lecturer Award of the Canadian Institutes for Health Research, the Genesis Award of BIOQuébec (for his outstanding contributions to life sciences), the Margolese National Heart Disorders Prize, and the Armand-Frappier Award of the Government of Québec (the highest scientific honour). Because of his accomplishments, Dr. Tardif was named Fellow of the Canadian Academy of Health Sciences (FCAHS) and was inducted in the Order of Canada (the highest distinction in the country).